Article

Combination glaucoma agents produce good control of IOP

Cincinnati, OH-The IOP-lowering effect of dorzolamide HCl/timolol maleate (Cosopt, Merck, West Point, PA) is comparable to that of brimonidine tartrate (Alphagan, Allergan, Irvine, CA) and timolol maleate after 6 months of treatment.

Related Videos
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Related Content
Retinal detachment risk after B1KPro
February 22nd 2025

Retinal detachment risk after B1KPro

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Sexual harassment remains high in ophthalmology
February 21st 2025

Sexual harassment remains high in ophthalmology

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

An illustration of an eye with a DNA helix in the pupil. Image credit: ©artacet – stock.adobe.com
February 20th 2025

Efficacy and safety findings for lenadogene nolparvovec (Lumevoq) from REFLECT Phase III trial

Seonix Bio launches SightScore testing service for primary open-angle glaucoma
February 20th 2025

Seonix Bio launches SightScore testing service for primary open-angle glaucoma

© 2025 MJH Life Sciences

All rights reserved.